BX Swiss TOP 30 CHF

BX Swiss TOP 30 CHF handeln
1.390,10 PKT -4,24 PKT -0,30 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN SL0CLV

ISIN DE000SL0CLV3


Analysen zu BX Swiss TOP 30 CHF-Werten

Datum Rating Analyst
17.01.12 Novartis buy Nomura
17.01.12 ABB (Asea Brown Boveri) outperform Credit Suisse Group
16.01.12 UBS neutral Banc of America Securities-Merrill Lynch
16.01.12 UBS buy Banc of America Securities-Merrill Lynch
16.01.12 Nestlé buy UBS AG
16.01.12 Partners Group overweight Morgan Stanley
16.01.12 Nestlé hold Vontobel Research
16.01.12 Lindt hold Vontobel Research
16.01.12 Holcim hold Vontobel Research
16.01.12 Novartis buy WestLB AG
16.01.12 Zurich Insurance buy Citigroup Corp.
16.01.12 Holcim neutral Exane-BNP Paribas SA
16.01.12 Holcim outperform Exane-BNP Paribas SA
13.01.12 UBS neutral UBS AG
13.01.12 Holcim hold Deutsche Bank AG
13.01.12 Holcim buy Deutsche Bank AG
13.01.12 Novartis buy Sarasin Research
13.01.12 Geberit buy Vontobel Research
13.01.12 Novartis hold Vontobel Research
12.01.12 Givaudan sell Citigroup Corp.
12.01.12 Zurich Insurance neutral Credit Suisse Group
12.01.12 Novartis buy Nomura
12.01.12 ABB (Asea Brown Boveri) buy Citigroup Corp.
12.01.12 Roche neutral Nomura
12.01.12 Geberit neutral Sarasin Research
11.01.12 Nestlé overweight J.P. Morgan Cazenove
11.01.12 Sika buy Vontobel Research
11.01.12 Schindler hold Vontobel Research
10.01.12 Zurich Insurance buy Société Générale Group S.A. (SG)
10.01.12 Sika buy Vontobel Research
09.01.12 Holcim sell Citigroup Corp.
09.01.12 UBS underperform Exane-BNP Paribas SA
09.01.12 Zurich Insurance buy Nomura
09.01.12 ABB (Asea Brown Boveri) neutral HSBC
09.01.12 Novartis kaufen Hamburger Sparkasse AG (Haspa)
09.01.12 Novartis hold Vontobel Research
09.01.12 Novartis outperform Sanford C. Bernstein and Co., Inc.
06.01.12 UBS overweight J.P. Morgan Cazenove
06.01.12 UBS overweight J.P. Morgan Cazenove
06.01.12 UBS outperform RBC Capital Markets